Expert report on immune checkpoint inhibitors for dMMR Colorectal Cancer

Expert report on neoadjuvant immune checkpoint inhibitors for NSCLCПодробнее

#ESMO22 Highlights on neoadjuvant ICI in locally advanced dMMR colon cancer: The NICHE-2 studyПодробнее

KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRCПодробнее

Immune checkpoint inhibitors in solid tumoursПодробнее

Combination Therapy & Clinical trials for Advanced HCC: What They Really Mean | Tumor Board Ep. 3Подробнее

Current and future trends in immunotherapy for MSI-H colorectal cancerПодробнее

Young-Onset Colorectal Cancer Center Annual Forum Research KeynoteПодробнее

Expert report on neoadjuvant immune checkpoint inhibitors for MelanomaПодробнее

How can we incorporate checkpoint inhibition in microsatellite stable colorectal cancer?Подробнее

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapyПодробнее

Significance of MSI Status and TMB in Metastatic CRCПодробнее

Immune Checkpoint and Inhibitor Colitis and Hepatitis: Expert ReviewПодробнее

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS studyПодробнее

Cancer Immune Checkpoint InhibitorsПодробнее

Lenvatinib and pembrolizumab in microsatellite stable CRCПодробнее

NCIS ISOS 2021 - Immunotherapy: A Review and Updates for SurgeonsПодробнее

Enhancing the efficacy of immune checkpoint inhibitors in CRCПодробнее

Limitations in immune checkpoint inhibitors in treating gastric cancerПодробнее

Immune checkpoint inhibitors in prostate cancer: Current and future practiceПодробнее